Zobrazeno 1 - 10 of 25 pro vyhledávání: '"P. A. Herzen Moscow"'
1
Ultrasound diagnosis of lymphoproliferative tumors in urologic oncology
Autor: Andrey Kaprin, O. A. Pavlova, P. A. Herzen Moscow, E. V. Prozorova, P. D. Bespalov, V. I. Kazakevich, L. A. Mitina, S. O. Stepanov, B. Ya, P. A. Herzen, N. G. Tyurina, M. V. Maiorova, M. A. Vernyuk, A. M. Chervontseva
Publikováno v: Onkologiya. Zhurnal imeni P.A.Gertsena. 4:29
Objective — to study the echographic semiotics of lymphoproliferative tumors in the presence of genitourinary system lesion. Material and methods. Forty-seven patients with non-Hodgkin lymphoma (NHL) and lymphogranulomatosis (LG) who had tumors in
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a3c5c2c4dc0bf2f3607bd6417588aca4
https://doi.org/10.17116/oncolog20154229-40
Zobrazit plný text záznamu
2
Simultaneous esophagectomy and lobectomy with bronchoplasty for synchronous esophageal and lung cancer
Autor: P. A. Herzen Moscow, I. V. Kolobaev, L. V. Telegina, V. M. Khomyakov, A. K. Kostrygin, N. N. Volchenko, P. A. Herzen, A. V. Chaika, A. B. Ryabov, V. V. Cheremisov, M. M. Shemetova, O. V. Pikin
Publikováno v: Onkologiya. Zhurnal imeni P.A.Gertsena. 4:53
The paper describes a rare clinical case of successful simultaneous surgery — esophagectomy and upper lobectomy with resection of the primary and intermediate bronchi for synchronous cancer of the thoracic esophagus and central cancer of the right
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::ab18a432d75afd072b40941bac3f12a8
https://doi.org/10.17116/onkolog20154253-56
Zobrazit plný text záznamu
3
Capabilities of ultrasound examination of mediastinal injury in patients with thyroid tumor
Autor: L. A. Mitina, P. A. Herzen Moscow, V. I. Kazakevich, A. K. Golubtsov, P. A. Herzen, N. S. Skreptsova, S. O. Stepanov, E. V. Prozorova
Publikováno v: Onkologiya. Zhurnal imeni P.A.Gertsena. 4:37
при опухолях щитовидной железы составила 86,5%, специфичность — 100%, точность — 94,0%. Ключевые слова: ультразвуковая диагностика, щитовидна
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::193440c31dc2b258ba19e378b6599574
https://doi.org/10.17116/onkolog20154137-44
Zobrazit plný text záznamu
5
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
Autor: Plimack ER; Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Elizabeth.Plimack@fccc.edu., Powles T; Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK., Stus V; Dnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine., Gafanov R; Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia., Nosov D; Central Clinical Hospital With Outpatient Clinic, Moscow, Russia., Waddell T; The Christie NHS Foundation Trust, Manchester, UK., Alekseev B; P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia., Pouliot F; CHU of Québec and Laval University, Québec, QC, Canada., Melichar B; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Soulières D; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Borchiellini D; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., McDermott RS; Adelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland., Vynnychenko I; Sumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine., Chang YH; Taipei Veterans General Hospital, Taipei, Taiwan., Tamada S; Bell Land General Hospital, Osaka, Japan., Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA., Li C; Merck & Co., Inc., Rahway, NJ, USA., Perini R; Merck & Co., Inc., Rahway, NJ, USA., Molife LR; MSD UK, London, UK., Bedke J; University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany., Rini BI; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Publikováno v: European urology [Eur Urol] 2024 Feb; Vol. 85 (2), pp. e58-e59. Date of Electronic Publication: 2023 Dec 08.
Zobrazit plný text záznamu
6
Akademický článek
Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study.
Autor: Plimack ER; Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Elizabeth.Plimack@fccc.edu., Powles T; Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK., Stus V; Dnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine., Gafanov R; Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia., Nosov D; Central Clinical Hospital With Outpatient Clinic, Moscow, Russia., Waddell T; The Christie NHS Foundation Trust, Manchester, UK., Alekseev B; P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia., Pouliot F; CHU of Québec and Laval University, Québec, QC, Canada., Melichar B; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Soulières D; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Borchiellini D; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., McDermott RS; Adelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland., Vynnychenko I; Sumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine., Chang YH; Taipei Veterans General Hospital, Taipei, Taiwan., Tamada S; Bell Land General Hospital, Osaka, Japan., Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA., Li C; Merck & Co., Inc., Rahway, NJ, USA., Perini R; Merck & Co., Inc., Rahway, NJ, USA., Molife LR; MSD UK, London, UK., Bedke J; University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany., Rini BI; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Publikováno v: European urology [Eur Urol] 2023 Nov; Vol. 84 (5), pp. 449-454. Date of Electronic Publication: 2023 Jul 25.
Zobrazit plný text záznamu
7
Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur. Urol. (2023)].
Autor: Plimack ER; Fox Chase Cancer Center, Philadelphia, PA, USA. Electronic address: Elizabeth.Plimack@fccc.edu., Powles T; Barts Health NHS Trust and the Royal Free NHS Foundation Trust, Barts Cancer Institute, London, UK; Queen Mary University of London, London, UK., Stus V; Dnipro State Medical University, Dnipro, Dnipropetrovsk Oblast, Ukraine., Gafanov R; Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia., Nosov D; Central Clinical Hospital With Outpatient Clinic, Moscow, Russia., Waddell T; The Christie NHS Foundation Trust, Manchester, UK., Alekseev B; P. A. Herzen Moscow Oncology Research Institute, Ministry of Health of the Russian Federation, Moscow, Russia., Pouliot F; CHU of Québec and Laval University, Québec, QC, Canada., Melichar B; Palacký University Medical School and Teaching Hospital, Olomouc, Czech Republic., Soulières D; Centre Hospitalier de l'Université de Montréal, Montréal, QC, Canada., Borchiellini D; Centre Antoine Lacassagne, Université Côte d'Azur, Nice, France., McDermott RS; Adelaide and Meath Hospital, University College Dublin, Belfield, Dublin, Ireland., Vynnychenko I; Sumy Regional Oncology Center, Sumy State University, Sumy, Sumy Oblast, Ukraine., Chang YH; Taipei Veterans General Hospital, Taipei, Taiwan., Tamada S; Bell Land General Hospital, Osaka, Japan., Atkins MB; Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, USA., Li C; Merck & Co., Inc., Rahway, NJ, USA., Perini R; Merck & Co., Inc., Rahway, NJ, USA., Rhoda Molife L; MSD UK, London, UK., Bedke J; University Hospital, Eberhard Karls University Tübingen, Tübingen, Germany., Rini BI; Vanderbilt-Ingram Cancer Center, Nashville, TN, USA.
Publikováno v: European urology [Eur Urol] 2023 Nov; Vol. 84 (5), pp. e123-e124. Date of Electronic Publication: 2023 Sep 02.
Zobrazit plný text záznamu
8
Akademický článek
Automated Assessment of the Area of Infiltration by CD8 + Cells in Gastric Carcinoma and Areas of Normal Mucosa as a Significant Prognostic Factor.
Autor: Danilova NV; Medical Scientific Educational Center, M. V. Lomonosov Moscow State University, Moscow, Russia. natalyadanilova@gmail.com., Mikhailov IA; Medical Scientific Educational Center, M. V. Lomonosov Moscow State University, Moscow, Russia., Khomyakov VM; P. A. Herzen Moscow Research Oncological Institute - Branch of National Medical Research Center of Radiology, Ministry of Health of the Russian Federation, Moscow, Russia., Chaika AV; P. A. Herzen Moscow Research Oncological Institute - Branch of National Medical Research Center of Radiology, Ministry of Health of the Russian Federation, Moscow, Russia., Polushkina TV; I. V. Davydovsky City Clinical Hospital, Moscow Healthcare Department, Moscow, Russia., Sotnikova TN; I. V. Davydovsky City Clinical Hospital, Moscow Healthcare Department, Moscow, Russia., Oleinikova NA; Medical Scientific Educational Center, M. V. Lomonosov Moscow State University, Moscow, Russia., Mal'kov PG; Medical Scientific Educational Center, M. V. Lomonosov Moscow State University, Moscow, Russia.
Publikováno v: Bulletin of experimental biology and medicine [Bull Exp Biol Med] 2023 Aug; Vol. 175 (4), pp. 508-512. Date of Electronic Publication: 2023 Sep 28.
Zobrazit plný text záznamu
9
Akademický článek
Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study.
Autor: Motzer R; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA. Electronic address: motzerr@mskcc.org., Porta C; Interdisciplinary Department of Medicine, University of Bari 'A Moro', Bari, Italy; Department of Biomedical Sciences and Human Oncology, University of Pavia, Pavia, Italy., Alekseev B; Department of Oncourology, P A Herzen Moscow Oncological Research Institute, Moscow, Russia., Rha SY; Yonsei Cancer Center, Yonsei University Health System, Seoul, South Korea., Choueiri TK; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Mendez-Vidal MJ; Maimonides Institute for Biomedical Research of Cordoba Hospital, Universitario Reina Sofía, Córdoba, Spain., Hong SH; Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea., Kapoor A; McMaster University, Hamilton, ON, Canada., Goh JC; ICON Research, South Brisbane and Queensland University of Technology, Brisbane, QLD, Australia., Eto M; Kyushu University, Fukuoka, Japan., Bennett L; RTI Health Solutions, Research Triangle Park, NC, USA., Wang J; RTI Health Solutions, Research Triangle Park, NC, USA., Pan JJ; Eisai, Nutley, NJ, USA., Saretsky TL; Merck & Co, Kenilworth, NJ, USA., Perini RF; Merck & Co, Kenilworth, NJ, USA., He CS; Eisai, Nutley, NJ, USA., Mody K; Eisai, Nutley, NJ, USA., Cella D; Department of Medical Social Sciences, Northwestern University, Chicago, IL, USA.
Publikováno v: The Lancet. Oncology [Lancet Oncol] 2022 Jun; Vol. 23 (6), pp. 768-780. Date of Electronic Publication: 2022 Apr 27.
Zobrazit plný text záznamu
10
Akademický článek
Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial.
Autor: Sweeney C; Dana-Farber Cancer Institute, Boston, MA, USA., Bracarda S; Azienda Ospedaliera Santa Maria, Terni, Italy., Sternberg CN; Englander Institute for Precision Medicine, Weill Cornell Medicine, New York-Presbyterian, New York City, NY, USA., Chi KN; BC Cancer, Vancouver, BC, Canada., Olmos D; Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Instituto de Investigación Biomédica de Málaga (IBIMA), Málaga, Spain., Sandhu S; Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, VIC, Australia., Massard C; Institut Gustave Roussy, Villejuif, France., Matsubara N; National Cancer Center Hospital East, Chiba, Japan., Alekseev B; P A Herzen Moscow Oncology Research Institute, Moscow, Russia., Parnis F; Ashford Cancer Centre Research, Kurralta Park, SA, Australia., Atduev V; Volga District Medical Centre under Federal Medical and Biological Agency of Russia, Nizhny Novgorod, Russia., Buchschacher GL Jr; Kaiser Permanente Southern California, Los Angeles Medical Center, Los Angeles, CA, USA., Gafanov R; Russian Scientific Center of Roentgenology and Radiology, Moscow, Russia., Corrales L; Medical Oncology, Centro de Investigación y Manejo del Cáncer CIMCA, San José, Costa Rica., Borre M; Aarhus University Hospital, Aarhus, Denmark., Stroyakovskiy D; Moscow City Oncology Hospital Number 62 of Moscow Healthcare Department, Moscow Oblast, Russia., Alves GV; Centro Integrado de Pesquisa em Oncologia, Hospital Nossa Senhora da Conceição, Porto Alegre, Brazil., Bournakis E; Oncologic Clinical Trials and Research Clinic, Metropolitan General Hospital, Athens, Greece., Puente J; Medical Oncology Department, Hospital Clínico San Carlos, Instituto de Investigación Sanitaria del Hospital Clínico San Carlos (IdISSC), CIBERONC, Madrid, Spain., Harle-Yge ML; F Hoffmann-La Roche, Basel, Switzerland., Gallo J; F Hoffmann-La Roche, Basel, Switzerland., Chen G; Genentech, South San Francisco, CA, USA., Hanover J; Genentech, South San Francisco, CA, USA., Wongchenko MJ; Genentech, South San Francisco, CA, USA., Garcia J; F Hoffmann-La Roche, Basel, Switzerland., de Bono JS; Division of Clinical Studies, The Institute of Cancer Research, London, UK; Drug Development Unit, Royal Marsden Hospital, Sutton, UK. Electronic address: johann.de-bono@icr.ac.uk.
Publikováno v: Lancet (London, England) [Lancet] 2021 Jul 10; Vol. 398 (10295), pp. 131-142.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje